

- **Name:** Yong-il Kim
 - **Current Position & Affiliation:** Assistant Professor, Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine
 - **Country:** Republic of Korea
-

- **Educational Background:**

Seoul National University

- Bachelor Degree of Medicine (2002 – 2008)
- Combined Master and Doctor Degree of Medical Science (2009 – 2016)

- **Professional Experience:**

Seoul National University Hospital

- Intern (2008 - 2009)
- Resident, Department of Nuclear Medicine (2009 – 2012)
- Research Fellow, Department of Nuclear Medicine (2013)

- **Professional Organizations:**

Seoul National University

- Senior Researcher, Medical Research Center (2016 – 2017)

CHA University

- Assistant Professor, Department of Nuclear Medicine (2017 – 2018)

University of Ulsan College of Medicine

- Assistant Professor, Department of Nuclear Medicine (Present)

- **Main Scientific Publications:**

1. Lee DY, Kim YI. Effects of ²²⁵Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis. J Nucl Med. 2021 Sep 9;jnumed.121.262017. doi: 10.2967/jnumed.121.262017. Epub ahead of print. PMID: 34503960.
2. Han S, Kim YI, Oh JS, Seo SY, Park MJ, Lee GD, Choi S, Kim HR, Kim YH, Kim DK, Park SI, Ryu JS. Diagnostic and prognostic values of 2-[¹⁸F]FDG PET/CT in resectable thymic epithelial tumour. Eur Radiol. 2021 Aug 26. doi: 10.1007/s00330-021-08230-z. Epub ahead of print. PMID: 34448035.
3. Kim YI, Ryu JS, Kim JK, Al-Dhafer BAA, Shin YH. Quantitative bone single-photon emission CT/CT parameters reflect pain and functional status of symptomatic basal joint arthritis of the thumb. Bone Joint J. 2021 Aug;103-B(8):1380-1385. doi: 10.1302/0301-

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- 620X.103B8.BJJ-2020-1826.R3. PMID: 34334043.
4. Kim YI, Lee HS, Choi JY. Prognostic Significance of Pretreatment 18F-FDG PET/CT Volumetric Parameters in Patients With Colorectal Liver Metastasis: A Systematic Review and Meta-analysis. *Clin Nucl Med.* 2021 Mar 1;46(3):206-213. doi: 10.1097/RLU.0000000000003479. PMID: 33443946.
 5. Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, Hong SM, Ryoo BY, Ryu JS. Tumour-to-liver ratio determined by [⁶⁸Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. *EJNMMI Res.* 2020 Jun 15;10(1):63. doi: 10.1186/s13550-020-00651-z. PMID: 32542576; PMCID: PMC7295884.
 6. Lee DY, Kim YI. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis. *Clin Nucl Med.* 2020 Aug;45(8):604-610. doi: 10.1097/RLU.0000000000003110. PMID: 32520503.
 7. Lee DY, Kim YI. Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis. *Clin Nucl Med.* 2019 Oct;44(10):777-783. doi: 10.1097/RLU.0000000000002694. PMID: 31283601.
 8. Kim YJ, Kim YI. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis. *Clin Nucl Med.* 2018 Oct;43(10):728-734. doi: 10.1097/RLU.0000000000002210. PMID: 30059428.